Diabetic Macular Edema -Epidemiology Forecast to 2027

Diabetic Macular Edema -Epidemiology Forecast to 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

50

Choose License

Final Price

DelveInsight's "Diabetic Macular Edema (DME) - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Diabetic Macular Edema (DME) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Diabetic Macular Edema (DME) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Diabetic Macular Edema (DME) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Diabetic Macular Edema (DME) outlook. It also includes the explanation of changing trends of epidemiology outlining the Diabetic Macular Edema (DME) scenario.

Diabetic Macular Edema (DME) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Diabetic Macular Edema (DME) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Diabetic Macular Edema (DME) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Diabetic Macular Edema (DME) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Diabetic Macular Edema (DME)

Key assessments
• Patient Segmentation in Diabetic Macular Edema (DME)
• Diabetic Macular Edema (DME) Risk & Burden
• Factors driving growth in a specific Diabetic Macular Edema (DME) patient population
1. Report Introduction
2. Diabetic Macular Edema (DME) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Diabetic Macular Edema (DME) in 2017
2.2. Patient Share Distribution of Diabetic Macular Edema (DME) in 2027
3. Disease Background and Overview: Diabetic Macular Edema (DME)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Diabetic Macular Edema (DME) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Diabetic Macular Edema (DME) in 7MM – By Countries
5. Epidemiology of Diabetic Macular Edema (DME) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.1.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME) *
5.1.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.1.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.4.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.4.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.4.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.5.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.5.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.5.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.6.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.6.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.6.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.7.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.7.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.7.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.8.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.8.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.8.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.9.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.9.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.9.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
6. Unmet Needs of the Diabetic Macular Edema (DME)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM
Table 2: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in United States (2016-2027)*
Table 5: Sex- Specific Cases of the Diabetic Macular Edema (DME) in United States (2016-2027)*
Table 6: Diagnosed Cases of the Diabetic Macular Edema (DME) in United States (2016-2027)
Table 7: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Germany (2016-2027)
Table 8: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Germany (2016-2027) *
Table 9: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Germany (2016-2027) *
Table 10: Diagnosed Cases of the Diabetic Macular Edema (DME) in Germany (2016-2027)
Table 11: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in France (2016-2027)
Table 12: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in France (2016-2027) *
Table 13: Sex- Specific Cases of the Diabetic Macular Edema (DME) in France (2016-2027) *
Table 14: Diagnosed Cases of the Diabetic Macular Edema (DME) in France (2016-2027)
Table 15: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Italy (2016-2027)
Table 16: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Italy (2016-2027) *
Table 17: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Italy (2016-2027) *
Table 18: Diagnosed Cases of the Diabetic Macular Edema (DME) in Italy (2016-2027)
Table 19: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Spain (2016-2027)
Table 20: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Spain (2016-2027) *
Table 21: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Spain (2016-2027) *
Table 22: Diagnosed Cases of the Diabetic Macular Edema (DME) in Spain (2016-2027)
Table 23: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in UK (2016-2027)
Table 24: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in UK (2016-2027) *
Table 25: Sex- Specific Cases of the Diabetic Macular Edema (DME) in UK (2016-2027) *
Table 26: Diagnosed Cases of the Diabetic Macular Edema (DME) in UK (2016-2027)
Table 27: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Japan (2016-2027)
Table 28: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Japan (2016-2027) *
Table 29: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Japan (2016-2027) *
Table 30: Diagnosed Cases of the Diabetic Macular Edema (DME) in Japan (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us